Current Trends in Biomedical Engineering & Biosciences
ISSN: 2572-1151

Juniper Publishers
key to the Researchers

Mini Review
Volume 24 Issue 2 - February 2026
DOI: 10.19080/CTBEB.2025.24.556131

Curr Trends Biomedical Eng & Biosci

Biomedical Engineering Strategies in Neural Stem Cell–Based Models of Parkinson's Disease: Current Advances and Translational Challenges

Piruz Shadbash[1]*

[1]*Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran*

Submission: February 12, 2026; **Published:** February 19, 2026

***Corresponding author**: Piruz Shadbash, department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran

Abstract

Parkinson's Disease (PD), a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc), remains a significant challenge for therapeutic intervention. Recent breakthroughs in deriving patient-specific DA neurons from Neural Stem Cells (NSCs) and induced Pluripotent Stem Cells (iPSCs) have revolutionized PD modeling. However, recapitulating the complex, three-dimensional (3D) microenvironment and interconnected cellular networks of the human midbrain in vitro remains a major hurdle. This mini-review surveys the critical role of biomedical engineering in overcoming these limitations. We detail how advanced engineering strategies, including sophisticated biomaterial scaffolds, microfluidic "brain-on-a-chip" systems, and bioelectronic interfaces are being leveraged to enhance the survival, maturation, functional integration, and disease phenotyping of stem cell-derived DA neurons. Emphasis is placed on strategies that mimic the native extracellular matrix (ECM) composition, mechanical properties, and localized signaling pathways essential for authentic PD pathology modeling. Finally, we discuss the significant translational challenges that bridge these highly engineered in vitro systems toward viable clinical applications, such as cell replacement therapy and high-throughput drug screening.

Keywords: Parkinson's Disease; Neural Stem Cells (NSCs); Induced Pluripotent Stem Cells (iPSCs); Biomedical Engineering; Brain-on-a-Chip; Bioelectronics

Abbreviations: NSCs: Neural Stem Cells; iPSCs: Induced Pluripotent Stem Cells; PD: Parkinson's Disease

Introduction

Parkinson's Disease (PD) affects millions globally, presenting with motor deficits stemming primarily from the degeneration of dopaminergic neurons in the SNpc. While pharmacological approaches offer symptomatic relief, they fail to halt disease progression or replace lost neurons [1]. The advent of human pluripotent stem cell technology, particularly iPSC generation and directed differentiation into midbrain DA progenitors, has provided unparalleled tools to study human-specific pathogenesis, screen compounds, and develop cell replacement therapies [2]. However, traditional 2D culture systems fail to adequately replicate the complex architectural, biomechanical, and cellular milieu of the native midbrain. This deficiency often results in immature phenotypes, aberrant maturation trajectories, and insufficient recapitulation of PD- specific pathologies, such as alpha-synuclein aggregation and mitochondrial dysfunction [3]. Consequently, biomedical engineering has emerged as an indispensable discipline, focusing on designing and fabricating functional, bio-mimetic microenvironments that guide stem cell differentiation and promote disease manifestation under physiologically relevant conditions [4]. This review focuses on the state-of-the-art engineering strategies employed to optimize NSC and iPSC-derived models for PD research, moving beyond simple cellular models toward functional tissue constructs.

Pathophysiology of Parkinson's Disease Relevant to Neural Engineering

PD pathophysiology is multifaceted, involving intracellular proteinopathy, mitochondrial dysfunction, neuroinflammation, and extracellular matrix (ECM) remodeling within the SNpc niche [5]. Key pathological hallmarks include.

a) **Alpha-Synuclein Pathy**: Misfolding and aggregation of alpha-synuclein alpha S into Lewy bodies is central to PD etiology. Engineering approaches must facilitate the propagation and aggregation of pathogenic alpha S strains in engineered tissues to model prion-like spread [6].

b) **Mitochondrial Dysfunction:** Deficiencies in Complex I of the electron transport chain, often modeled using rotenone or 6-hydroxydopamine (6-OHDA) exposure, lead to oxidative stress. Engineering the local microenvironment (e.g., oxygen tension) can modulate this sensitivity [7].

c) **The Midbrain Niche:** DA neurons reside within a highly specific niche characterized by precise topographic organization, supporting glial cells (astrocytes and microglia), and distinct biomechanical cues derived from the surrounding basement membrane. The mechanical stiffness of the ECM is critical; native brain tissue possesses low stiffness, typically ranging from 0.1 to 1 kPa [8]. Deviation from this stiffness impacts neuronal polarization and maturation.

Neural Stem Cells and iPSC-Derived Dopaminergic Neurons in PD

The shift from rodent primary neurons to human iPSC-derived DA neurons is critical because iPSC lines preserve patient-specific genetic backgrounds (e.g., LRRK2 mutations, SNCA duplications). Protocols now reliably produce TH (Tyrosine Hydroxylase) neurons expressing markers consistent with A9/A10 midbrain identity [9]. However, achieving functional maturity remains challenging. In vitro DA neurons often exhibit a fetal electrophysiological profile, lacking the complex firing patterns and appropriate neurotransmitter release characteristics of adult SNpc neurons [10]. Biomedical engineering intervenes here by providing physical and biochemical cues that drive this maturation process. For example, providing structured substrates or incorporating glial support populations within engineered constructs has shown promise in promoting adult-like characteristics, including the expression of functional dopamine transporters DAT and appropriate firing frequencies [11].

Biomedical Engineering Approaches

Biomedical engineering strategies aim to reconstruct the 3D structural, chemical, and mechanical complexity of the native SNpc environment to optimize stem cell fate, function, and pathology manifestation.

Biomaterials and Hydrogels

Hydrogels, crosslinked polymeric networks that mimic the high water content and compliance of biological tissues, are foundational for 3D culture [12]. For PD modeling, the material must balance biocompatibility, tuneable mechanical properties, and cell-instructive cues.

I. **Mechanical Tuning:** Materials like Matrigel, fibrin, or synthetic polymers (e.g., PEGDA, hyaluronic acid) allow for precise control over Young's Modulus E. Studies have shown that maintaining substrate stiffness in the range of 0.5 kPa to 5 kPa promotes neuronal differentiation and neurite outgrowth compared to rigid plastic (>1 Gaps) [13].

II. **Biochemical Functionalization:** The incorporation of cell-adhesion ligands (RGD) motifs or specific ECM proteins (e.g., laminin, fibronectin) within the hydrogel matrix guides neuronal migration, polarization, and synaptic connectivity, crucial for forming functional circuitry in PD models [14].

3D Neural Scaffolds

Beyond bulk hydrogels, porous scaffolds provide defined topographical guidance. Techniques such as 3D printing (bioprinting) and electrospinning allow for the creation of aligned architectures that mimic the directionality of white matter tracts. In PD models, these scaffolds can spatially organize progenitor cells and support cells, ensuring the uniform differentiation and integration of DA neurons into structures resembling the SNpc circuitry, thereby improving the relevance of alpha S propagation studies [15].

Midbrain Organoids

Midbrain organoids represent the apex of spontaneous self-organization techniques, grown from iPSCs into complex, three-dimensional structures that spontaneously form neural layers and rudimentary regional identity, including TH neurons [16]. Engineering efforts focus on:

a) **Size and Nutrient/Oxygen Transport:** Larger organoids suffer from central necrosis due to diffusion limitations. Bioreactors and microfluidic perfusion systems are employed to ensure uniform oxygen O and nutrient supply throughout the structure, maintaining viability and functional integrity necessary for chronic PD modeling [17].

b) **Homogeneity and Region Specificity:** Controlling the initial patterning cues e.g., using morphogens like SHH and WNT1 within the scaffold microenvironment ensures a higher yield of genuine midbrain structures rather than cortical or hindbrain contaminants [18].

Microfluidic Brain-on-a-Chip Systems

Microfluidics integrates the advantages of defined chemical

How to cite this article: Piruz S. Biomedical Engineering Strategies in Neural Stem Cell–Based Models of Parkinson's Disease: Current Advances and Translational Challenges. Curr Trends Biomedical Eng & Biosci. 2026; 24(2): 556131. DOI: 10.19080/CTBEB.2026.24.5560131

gradients and spatial control. Brain-on-a-Chip (BoC) systems are engineered to connect distinct cellular compartments representing different brain regions or to precisely control the supply of pathological agents [19].

a) Modeling Neurovascular Unit: BoCs can integrate endothelial cells to form a blood-brain barrier (BBB), allowing researchers to study how systemic toxins or therapeutic agents cross the (BBB) to induce localized DA neuron damage, a key consideration for testing neuroprotective drugs [20].

b) Precise Neurotransmitter Modeling: Flow control allows for the timed and concentration-specific application of dopamine agonists or toxins (e.g., 6-OHDA), providing a dynamic platform superior to static cultures for observing acute cellular responses relevant to PD progression [21].

Electrical and Bioelectronic Stimulation Strategies

Bioelectronic interfaces bridge the gap between biological function and electronic measurement/modulation [22]. These technologies are vital for assessing the functional output of engineered neural tissue:

a) Multi-Electrode Arrays (MEAs): Integrated into culture platforms, (MEAs) allow for non-invasive, long-term monitoring of network activity, action potential firing, and synaptic transmission between engineered DA neurons and their targets. Changes in spiking patterns due to PD pathology (e.g., bursting behavior) can be quantified [23].

b) Optogenetics and Chemogenetics: While not strictly bioelectronic, integrating genetic tools allows for electrically or chemically induced activation/inhibition of specific neuronal populations (e.g., TH neurons) within the engineered construct, enabling precise mapping of circuitry dysfunction relevant to PD motor symptoms.

Translational and Clinical Challenges

The primary clinical application of these advanced models is two-fold: improved drug screening and the development of cell replacement therapies. Significant engineering hurdles must be overcome for translation.

a) Standardization and Robustness: Current organoid protocols often suffer from batch-to-batch variability. Developing standardized, scalable bioreactors and robust scaffolding techniques that guarantee uniform cell identity, maturation state, and pathological responsiveness across different laboratories is paramount for clinical utility [24].

b) Modeling Disease Progression: While acute PD modeling is feasible, recapitulating the decades-long, slow degeneration seen in idiopathic PD requires long-term stability (>6 months) in engineered tissues without degradation or loss of neuronal identity [24].

c) Vascularization: For any future cell graft or large tissue model intended for implantation or long-term study, adequate vascularization is essential to supply oxygen and nutrients, a challenge largely unsolved in current organoid engineering [25].

d) Assessing Functional Efficacy in Cell Therapy: Before transplantation, stem cell grafts must demonstrate robust integration and functional dopamine release in vivo. Engineered matrices that allow for the pre-assessment of functional integration (e.g., electrophysiological coupling on a chip prior to implantation) are required [26].

Future Directions

Future efforts will focus on true multiscale integration:

a) Tissue Integration: Combining advanced biofabrication with vascular engineering to create perfusion-enabled, thick engineered tissues that mimic the architecture of the basal ganglia circuits.

b) Closed-Loop Systems: Developing AI-driven feedback loops where sensors within a BoC monitor pathological biomarkers alpha S burden, metabolic stress) and autonomously adjust microenvironmental parameters (pH, shear stress, nutrient flow) to maintain homeostasis or drive specific disease states for optimal modeling fidelity.

c) Genotype-Phenotype Correlation: Utilizing CRISPR/Cas9 editing within iPSC lines, coupled with engineered scaffolds that force specific cell-cell interactions, to dissect the precise molecular pathways affected by distinct PD-associated genetic risk factors.

Conclusion

Biomedical engineering has transformed PD modeling from a cellular study into a sophisticated tissue engineering endeavor. By applying principles of biomaterials science, microfluidics, and bioelectronics, researchers are creating increasingly sophisticated, patient-relevant models utilizing NSCs and iPSCs. These engineering strategies are essential for pushing beyond simple morphology toward functional recapitulation of complex PD pathology. While significant hurdles remain in scaling, standardization, and long-term stability, the continued synergy between neuroscience and bioengineering promises to unlock novel therapeutic targets and refine cell replacement strategies for Parkinson’s Disease.

References

1. Ramesh S, Arachchige ASPM (2023) Depletion of dopamine in Parkinson’s disease and relevant therapeutic options: A review of the literature. AIMS neuroscience 10: 200.
2. Takahashi J (2025) iPSC-based cell replacement therapy: From basic research to clinical application. Cytotherapy.

How to cite this article: Piruz S. Biomedical Engineering Strategies in Neural Stem Cell–Based Models of Parkinson’s Disease: Current Advances and Translational Challenges. Curr Trends Biomedical Eng & Biosci. 2026; 24(2): 556131. DOI: 10.19080/CTBEB.2026.24.5560131

3. Yeap YJ (2023) From 2D to 3D: development of monolayer dopaminergic neuronal and midbrain organoid cultures for Parkinson's disease modeling and regenerative therapy. International journal of molecular sciences 24: 2523.
4. Zheng F (2024) Droplet Microfluidics Powered Hydrogel Microparticles for Stem Cell-Mediated Biomedical Applications. Small 20: 2401400.
5. Dolgacheva LP (2022) Molecular and cellular interactions in pathogenesis of sporadic Parkinson disease. International journal of molecular sciences 23: 13043.
6. Arias-Carrión O (2025) α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges. International Journal of Molecular Sciences 26: 5405.
7. Okyere SK (2021) Neurotoxic mechanism and shortcomings of MPTP, 6-OHDA, rotenone and Paraquat-induced Parkinson's disease animal models. Venoms and Toxins 1: 27-40.
8. Brignani S, Pasterkamp R (2017) Neuronal subset-specific migration and axonal wiring mechanisms in the developing midbrain dopamine system. Frontiers in Neuroanatomy 11: 55.
9. Juan RT. Using patient-specific iPSC derived dopaminergic neurons to investigate Parkinson's disease: a new prospective in stem cell research and application.
10. Guatteo E (2022) Pathophysiological features of nigral dopaminergic neurons in animal models of Parkinson's disease. International journal of molecular sciences 23: 4508.
11. Acero VP (2024) Tissue Engineered Multi-Aggregate Cortical-Hippocampal Neural Networks for Pharmacological Investigations. University of Pennsylvania.
12. Fan D (2019) Engineered 3D polymer and hydrogel microenvironments for cell culture applications. Bioengineering 6: 113.
13. Yang P (2025) Test and tune: evaluating, adjusting and optimising the stiffness of hydrogels to influence cell fate. Chemical Engineering Journal pp. 159295.
14. Morwood AJ (2023) The role of extracellular matrix (ECM) adhesion motifs in functionalised hydrogels. Molecules 28: 4616.
15. Honkamäki L (2025) Hyaluronic Acid-Based 3D Bioprinted Hydrogel Structure for Directed Axonal Guidance and Modeling Innervation In Vitro. Advanced Healthcare Materials 14: 2402504.
16. Sabaté Soler S (2022) Increasing the Complexity of Midbrain Organoid Systems for Developmental studies and Disease Modelling.
17. Nwokoye PN, Abilez OJ (2024) Bioengineering methods for vascularizing organoids. Cell Reports Methods p. 4.
18. Brady MV, Vaccarino FM (2021) Role of SHH in patterning human pluripotent cells towards ventral forebrain fates. Cells 10: 914.
19. Wang Z (2023) Microfluidic brain-on-a-chip: from key technology to system integration and application. Small 19: 2304427.
20. Cameron T (2021) Review of design considerations for brain-on-a-chip models. Micromachines 12: 441.
21. Jiang XR, Zhu BT (2025) Facile Biological Oxidation of Dopamine to 6-Hydroxydopamine p-Quinone in a Sequential Two-Step Process: Implications for Parkinson's Disease. Chemical Research in Toxicology.
22. Prominski A, Tian B (2021) Bridging the gap-Biomimetic design of bioelectronic interfaces. Current Opinion in Biotechnology 72: 69-75.
23. Grasselli S (2025) In vitro electrophysiological characterization of Parkinson's disease: Challenges, advances, and future directions. Frontiers in Neuroscience 19: 1584555.
24. Chaudhary N, Villa-Diaz LG (2025) Advancements in the in vitro culture of human pluripotent stem cells: progress, challenges, and future directions: comprehensive review. Frontiers in Toxicology 7: 1667573.
25. Rademakers T (2019) Oxygen and nutrient delivery in tissue engineering: Approaches to graft vascularization. Journal of tissue engineering and regenerative medicine 13: 1815-1829.
26. Storm P (2024) Lineage tracing of stem cell–derived dopamine grafts in a Parkinson's model reveals shared origin of all graft-derived cells. Science Advances.

DOI: 10.19080/CTBEB.2026.24.5560131